Estimation of antiphospholipid antibodies in a prospective longitudinal study of children with migraine

Cephalalgia

Volumn 24, Issue 10, 2004, Pages 831-837

  Avcin, Tadej ^a   Markelj, G ^a   Niksic, V ^a   Rener Primec, Z ^a   Cucnik, S ^b   Zupancic, M ^a   Rozman, B ^b   Neubauer, D ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Anti 2 glycoprotein I antibodies; Anticardiolipin antibodies; Antiphospholipid antibodies; Childhood; Lupus anticoagulant; Migraine

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PROSPECTIVE STUDY; TENSION HEADACHE;

ADOLESCENT; ANTIBODIES, ANTIPHOSPHOLIPID; CHI-SQUARE DISTRIBUTION; CHILD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIGRAINE DISORDERS; PROSPECTIVE STUDIES; STATISTICS;

EID: 4844220202     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00752.x     Document Type: Article

References (27)

1. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. Br Med J 1994; 309:765-9.
2. Split W, Neuman W. Epidemiology of migraine among students from randomly selected secondary schools in Lodz. Headache 1999; 39:494-501.
3. Frare M, Axia G, Battistella PA. Quality of life, coping strategies, and family routines in children with headache. Headache 2002; 42:953-62.
4. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. Pediatrics 2003; 112:e1-5.
5. Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia 1995; 15:277-80.
6. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001; 53:167-78.
7. Kemper RH, Meijler WJ, Korf J, Ter Horst GJ. Migraine and function of the immune system: a meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia 2001; 21:549-57.
8. Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 90:29-37.
9. Angelini L, Zibordi F, Zorzi G, Nardocci N, Caporali R, Ravelli A, et al. Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. Neuropediatrics 1996; 27:149-53.
10. Verrotti A, Cieri F, Pelliccia P, Morgese G, Chiarelli F. Lack of association between antiphospholipid antibodies and migraine in children. Int J Clin Laboratory Res 2000; 30:109-11.
11. 2 glycoprotein I and induce endothelial activation. Arthritis Rheum 1997; 40:551-61.
12. Pierangeli SS, Espinola RG, Liu X, Harris N. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88:245-50.
13. Caronti B, Pittoni V, Palladini G, Valesini G. Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci 1998; 156:211-9.
14. Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, et al. Endothelial activation by aPL. a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000; 15:237-40.
15. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7:1-96.
16. 2 glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology 2001; 40:565-73.
17. 2 glycoprotein I antibodies and lupus anticoagulant in a prospective longitudinal study of children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2002; 20:101-8.
18. 2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on antiphospholipid antibodies standardization group. Thromb Haemost 2002; 88:66-73.
19. 2-glycoprotein I antibodies. Arthritis Rheum 1999; 42:2461-70.
20. 2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37:1453-61.
21. Harris EN. The second international anti-cardiolipin standardization workshop/The Kingston anti-phospholipid antibody study (KAPS) group. Am J Clin Pathol 1990; 94:476-84.
22. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74:1185-90.
23. Bunn C, Kveder T. Counterimmunoelectrophoresis and immunodiffusion for the detection of antibodies to soluble cellular antigens. In: Van Venrooij WJ, Maini RN, editors. Manual of biological markers of disease. Dordrecht: Kluwer Academic Publishers, 1996:A3, 1-12.
24. Buring JE, Hebert P, Romero J, Kittross A, Cook N, Manson J, et al. Migraine and subsequent risk of stroke in the Physicians' Health Study. Arch Neurol 1995; 52:129-34.
25. Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N. Association between migraine and stroke in a large scale epidemiological study of the United States. Arch Neurol 1997; 54:362-8.
26. Tietjen GE, Day M, Norris L, Aurora S, Halvorsen A, Schultz LR, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events. Neurology 1998; 50:1433-40.
27. Cuadrado MJ, Khamashta MA, Hughes GRV. Migraine and stroke in young women. Q J Med 2000; 93:317-9.